All In Biotech

Free tool

FAERS Monitor: Baqsimi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210134 or its brand name (Baqsimi, Glucagon). Reports on generic versions are filed under their own applications.

Reports

4,232

Serious

3,276

77% of reports

Hospitalization

2,036

Death reported

676

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective389
  • dyspnoea375
  • acute kidney injury324
  • hypotension300
  • hypoglycaemia271
  • condition aggravated258
  • toxicity to various agents238
  • nausea237
  • anxiety226
  • haemoptysis224
  • vomiting222
  • death213
  • pain in extremity212
  • off label use206
  • blood glucose increased201

Reports by year received

View as table
YearReports
200419
200524
200620
200726
200823
200949
201034
201153
201253
201354
201483
2015230
2016202
2017210
2018207
2019323
2020448
2021436
2022316
2023398
2024369
2025392
2026263

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,927 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
haemoptysisSignal22440.235.48,474
hypoglycaemiaSignal27127.924.96,984
acute kidney injurySignal32410.59.52,803
hypotensionSignal3007.46.71,680
toxicity to various agentsSignal2387.06.21,231
blood glucose increasedSignal2015.34.6704
condition aggravatedSignal2584.23.7639
anxietySignal2263.93.5501
pain in extremitySignal2123.63.1396
dyspnoeaSignal3753.33.0613
vomitingSignal2222.32.1174
nausea2371.51.339
drug ineffective3891.51.361
death2131.21.19
off label use2061.21.05

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.